The choice of more than 36,000 U.S. health professionals and a leading brand in Europe

Who We Are

Pure Encapsulations was founded to formulate and manufacture the highest quality line of hypo-allergenic supplements available. Since our inception, we have been the industry leader in manufacturing excellence and quality control, as well as a pioneer in the production of research-based and clinically relevant formulas.

There are currently 19 ongoing or completed research trials involving Pure Encapsulations products, including studies at Stanford University, Michigan State and the Mayo Clinic.

In 2004, Pure was acquired by Atrium Innovations Inc. Atrium Innovations Inc. is a recognized leading developer, manufacturer and marketer of science-based and professionally endorsed products for the health and nutrition industries.

Pure Encapsulations is committed to producing the most complete line of research-based nutritional supplements. Available through health professionals, finished products are pure and hypoallergenic to optimize the long-term health of all patients, even the most sensitive.

Pure Encapsulations is committed to:

  • Hypoallergenic supplements, free from allergens, binders, fillers, GMO, magnesium stearate
  • Professional strength products backed by research
  • Open plant policy
  • GMP Manufacturing
  • Full label disclosure
  • Corporate and Social Responsibility

Quality Control

We manufacture our own products in our own state-of-the-art plant in Sudbury, Massachusetts. Pure Encapsulations is NSF-GMP registered in the U.S., GMP certified in Canada and exceeds the standards of the United States Pharmacopeia(USP).

Social Responsibility

Pure Encapsulations is committed to supporting local and worldwide communities through outreach efforts and environmental initiatives.

Medical Advisory Board

Pure Encapsulations is dedicated to advancing the research and clinical applications of dietary supplements in health and wellness.
We collaborate with leading researchers worldwide in an effort to identify novel cellular targets and mechanisms, specifically those that influence health outcomes at the genomic level.